We aimed to provide a significant contribution to early recognition of pulmonary vascular diseases including pulmonary hypertension via novel and non-invasive methods and to develop innovative therapeutic strategies for an improved prognosis and better quality of life for the victims of this serious disease. The integrative, multidisciplinary and translational structure of the LBI-LVR allowed it to uncover underlying molecular pathways, identify distinct targets for reverse-remodelling therapy, foster drug development based on these targets, and prove these new treatment options in preclinical and clinical proof-of-concept trials.